Pharmacokinetics Government Bids & RFPs

Responses are requested no later than July 29, 2026, **** Eastern Standard Time. Please submit all capability statements directly to the contracting officer for review no later than nlt july 29, 2026 **** eastern standard time.

Vendors must demonstrate technical capability and experience performing GLP toxicology studies, rodent PK studies, LC-MS/MS analysis, histopathology, necropsy, and relevant past performance for biomedical R&D or FDA preclinical support. Demonstrated technical capability and experience performing: glp toxicology studies rodent pk studies lc ms ms analysis histopathology and necropsy relevant past performance for biomedical r d or fda preclinical support.

The anticipated period of performance is one year, approximately September 15, 2026 through September 14, 2027.

The contract is expected to start December 1, 2026, to November 30, 2027, with four 12-month renewal options.

Payment shall be made monthly in arrears for services provided during the billing month, upon submission of a properly prepared invoice.

Interested contractors shall submit a capabilities qualifications statement to include an overview of proposed solutions and a description of the product.

If market research table questionnaire information is not provided, it will be assumed the entire requirement cannot be met.

Proposals are due by **** hours, June 12, 2026.

Proposals will be evaluated to select the best submission.

The government will evaluate pre-proposals and may request full proposals. Awards are dependent upon the availability of funds and fulfillment of requirements and priorities.

The government is prohibited from soliciting and awarding actions to awardees that have engaged or are suspected to have engaged in criminal, fraudulent, or seriously improper conduct.

Proposals are due by 4:00 PM EST on May 28, 2026.

The contract will be a cost-reimbursement type, with invoices submitted to the Department of Treasury's Invoice Processing Platform (IPP).

The government intends to award a contract to the responsible offeror whose proposal represents the best value after evaluation, with technical factors being significantly more important than cost.

Offerors must have a valid and current drug establishment registration with the FDA and demonstrate capability for activities under GMP. They must also have GLP-compliant laboratory capabilities and adequate animal research facilities.

The contract may be subject to various penalties and remedies as outlined in the Federal Acquisition Regulation (FAR) and HHS Acquisition Regulation (HHSAR) clauses, including those related to late submissions and non-compliance.

The solicitation does not explicitly mention a site visit requirement for offerors.

The solicitation does not explicitly mention a requirement for sample submission as part of the proposal.

The solicitation does not specify a deadline for challenging the bid or award.

The maximum estimated total value for this contract is $49,000,000.